miltefosine has been researched along with Emesis in 6 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 9.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 9.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 5.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
| "34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 5.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
| "Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance." | 2.75 | Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. ( Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L, 2010) |
| "Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection." | 2.69 | Trial of oral miltefosine for visceral leishmaniasis. ( Goyal, AK; Hilgard, P; Makharia, MK; Mandal, AK; Murray, HW; Rosenkaimer, F; Sundar, S; Voss, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Machado, PR | 1 |
| Ampuero, J | 1 |
| Guimarães, LH | 1 |
| Villasboas, L | 1 |
| Rocha, AT | 1 |
| Schriefer, A | 1 |
| Sousa, RS | 1 |
| Talhari, A | 1 |
| Penna, G | 1 |
| Carvalho, EM | 1 |
| Stekar, J | 1 |
| Hilgard, P | 2 |
| Voegeli, R | 1 |
| Maurer, HR | 1 |
| Engel, J | 1 |
| Kutscher, B | 1 |
| Nössner, G | 1 |
| Schumacher, W | 1 |
| Verweij, J | 2 |
| Krzemieniecki, K | 1 |
| Kok, T | 1 |
| Poveda, A | 1 |
| van Pottelsberghe, C | 1 |
| van Glabbeke, M | 1 |
| Mouridsen, H | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Sundar, S | 2 |
| Rosenkaimer, F | 1 |
| Makharia, MK | 1 |
| Goyal, AK | 1 |
| Mandal, AK | 1 |
| Voss, A | 2 |
| Murray, HW | 2 |
| Makharia, A | 1 |
| More, DK | 1 |
| Agrawal, G | 1 |
| Fischer, C | 1 |
| Bachmann, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control[NCT00600548] | Phase 2 | 180 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
5 trials available for miltefosine and Emesis
| Article | Year |
|---|---|
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazi | 2010 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin | 1993 |
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk | 1993 |
Trial of oral miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Drug Administration Schedule; Humans; | 1998 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H | 2000 |
1 other study available for miltefosine and Emesis
| Article | Year |
|---|---|
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Female; Ferr | 1993 |